欧洲抗凝逆转药物市场预测至 2027 年 - COVID-19 影响和按产品进行区域分析（凝血酶原复合物浓缩物、维生素 K、鱼精蛋白、氨甲环酸、Idarucizumab 和 AndeXXa）；最终用户（医院药房、零售药房等）
No. of Pages: 146 | Report Code: TIPRE00022194 | Category: Life Sciences
No. of Pages: 146 | Report Code: TIPRE00022194 | Category: Life Sciences
在某些情况下需要抗凝逆转药物来逆转抗凝效果，例如计划外手术、抗凝治疗过量、和不受控制的出血。在静脉血栓栓塞、心房颤动 (AF)、机械瓣膜置换术和其他凝血障碍（如抗磷脂抗体综合征、V 因子 Leiden）等疾病中，使用抗凝逆转药物。
因此，患病率不断增加预计未来几年中风的发生将对抗凝逆转药物产生巨大需求，预计这将进一步推动抗凝逆转药物市场的发展。
欧洲抗凝逆转药物市场预计将从 270.0 美元增长从 2019 年的 100 万美元增至 2027 年的 6.554 亿美元；预计 2019 年至 2027 年复合年增长率为 12.4%。世界各地针对心房颤动等心血管疾病日益流行的新型疗法的药物开发研究活动迅速进展，正在推动抗凝药物逆转的增长药品市场。各种心血管适应症的治疗始终需要创新的治疗方法。例如，题为“评估 andexanet alfa 和四因子凝血酶原复合物浓缩物 (4F- PCC) 逆转利伐沙班”的研究/span> 和阿哌沙班 相关的颅内出血，”于 2020 年 2 月发表，旨在研究 andexanet alfa 治疗颅内出血 (ICH) 的疗效。这促进了抗凝逆转药物市场的增长。
从产品来看，凝血酶原复合物浓缩液细分市场在2019年欧洲抗凝逆转药物市场中占据最大份额。从分销渠道来看，医院药房2019年抗凝逆转药物市场占有较大市场份额。
一些准备本欧洲抗凝逆转药物市场报告时参考的主要一手和二手来源包括公司网站、年度报告、财务报告、国家政府文件和统计数据库等。报告中列出的主要公司有勃林格殷格翰国际有限公司
按产品
通过分销渠道
按国家/地区
Strategic insights for Europe Anticoagulant Reversal Drug involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 270.0 Million |
| Market Size by 2027 | US$ 655.4 Million |
| Global CAGR (2019 - 2027) | 12.4% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By 产品
|
| Regions and Countries Covered | 欧洲
|
| Market leaders and key company profiles |
The regional scope of Europe Anticoagulant Reversal Drug refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Anticoagulant Reversal Drug Market is valued at US$ 270.0 Million in 2019, it is projected to reach US$ 655.4 Million by 2027.
As per our report Europe Anticoagulant Reversal Drug Market, the market size is valued at US$ 270.0 Million in 2019, projecting it to reach US$ 655.4 Million by 2027. This translates to a CAGR of approximately 12.4% during the forecast period.
The Europe Anticoagulant Reversal Drug Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Anticoagulant Reversal Drug Market report:
The Europe Anticoagulant Reversal Drug Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Anticoagulant Reversal Drug Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Anticoagulant Reversal Drug Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Anticoagulant Reversal Drug Market
